[Therapy of cutaneous metastases of malignant melanoma].
Malignant melanoma represents a particular challenge for dermatologists and oncologists because of its high and increasing incidence and the poor prognosis of patients with thick primary tumors (T3, T4). In advanced stages of melanoma, cutaneous and subcutaneous metastases have a special significance, as they markedly affect the patient and may lead to a limitation in quality of life. While topical therapy is possible, there are only limited clinical studies. The location, number, size and distribution of skin metastases, involvement of internal organs, age and general condition should be considered in assessing therapeutic options. Especially with solitary, easily accessible metastases, surgical excision represents the therapy of choice. Ablation using CO(2) laser is an alternative. With extensive metastases in just one extremity, isolated limb perfusion (ILP) with melphalan is an option, while multiple, smaller metastases can be irradiated. Further, several chemotherapeutic agents and immune modulators can be used topically, peri- and intralesionally.
Rehberger
P
P
Klinik und Poliklinik für Dermatologie am Universitätsklinikum Carl Gustav Carus, Fetscherstrasse 74, 01307 Dresden. philipp.rehberger@uniklinikum-dresden.de
Eppinger
S
S
Stein
A
A
Schmitt
J
J
D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D006801:Humans; D053685:Laser Therapy / Q000379:methods*; D008545:Melanoma / Q000556:secondary* / Q000628:therapy*; D008558:Melphalan / Q000008:administration & dosage*; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians'; D011878:Radiotherapy / Q000379:methods*; D012878:Skin Neoplasms / Q000556:secondary* / Q000628:therapy*
D018906:Antineoplastic Agents, Alkylating; D008558:Melphalan